| Dec'19 | Dec'18 | Dec'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 |
|---|---|---|---|---|---|---|---|---|
Net sales | ||||||||
3,162 | 3,215 | 3,221 | 3,380 | 2,923 | 1,650 | 1,712 | 2,056 | 2,021 |
Cost of sales | ||||||||
1,741 | 1,744 | 1,564 | 1,523 | 1,300 | 765 | 890 | 1,091 | 1,106 |
Gross profit | ||||||||
1,421 | 1,471 | 1,657 | 1,857 | 1,622 | 884 | 822 | 964 | 914 |
Selling, general and administrative expenses | ||||||||
831 | 834 | 849 | 913 | 1,023 | 611 | 495 | 551 | 532 |
Research and development expenses | ||||||||
349 | 361 | 276 | 261 | 203 | 140 | 157 | 144 | 141 |
Restructuring charges, net | ||||||||
-1 | 103 | 31 | 32 | 45 | 68 | 23 | 11 | 8 |
Separation Costs | ||||||||
- | - | - | - | 0 | 9 | 74 | 25 | 2 |
Non-restructuring impairment charges | ||||||||
388 | 3,893 | 63 | 16 | 0 | 27 | - | - | - |
Losses (gains) on divestiture | ||||||||
-33 | -0 | 56 | 0 | 3 | - | - | - | - |
Opioid-related litigation settlement (Note 11) | ||||||||
1,643 | 0 | 0 | - | - | - | - | - | - |
Nonoperating Gains (Losses) | ||||||||
- | - | - | - | - | 15 | - | - | - |
Losses (gains) on divestiture | ||||||||
- | - | - | - | 3 | 15 | 2 | 2 | 11 |
Operating Income (Loss) | ||||||||
-1,822 | -3,720 | 492 | 633 | 353 | 43 | 73 | 235 | 240 |
Interest expense | ||||||||
309 | 370 | 369 | 384 | 255 | 82 | 19 | 0 | 0 |
Interest income | ||||||||
9 | 8 | 4 | 1 | 1 | 1 | 0 | 0 | 0 |
Gain (Loss) on Extinguishment of Debt | ||||||||
466 | 8 | 8 | - | - | - | - | - | - |
Other income, net | ||||||||
63 | 22 | -75 | -16 | 8 | 3 | 1 | 1 | 2 |
Loss from continuing operations before income taxes | ||||||||
-1,591 | -4,052 | 61 | 233 | 107 | -34 | 55 | 236 | 243 |
Income tax benefit | ||||||||
-584 | -430 | -1,709 | -255 | -129 | -12 | 47 | 94 | 86 |
(Loss) income from continuing operations | ||||||||
-1,007 | -3,621 | 1,771 | 489 | 236 | -22 | 8 | 141 | 157 |
Income (loss) from discontinued operations, net of income taxes | ||||||||
10 | 14 | 363 | 154 | 88 | -297 | 50 | -6 | -6 |
Net (loss) income | ||||||||
-996 | -3,607 | 2,134 | 643 | 324 | -319 | 58 | 134 | 150 |
Basic (loss) earnings per share (Note 5): | ||||||||
Income (loss) from continuing operations, per share | ||||||||
-12.00 | -43.12 | 18.13 | 4.42 | 2.03 | -0.34 | 0.14 | 2.45 | 2.72 |
Income from discontinued operations, per share | ||||||||
0.13 | 0.18 | 3.72 | 1.40 | 0.75 | -4.58 | 0.88 | -0.12 | -0.11 |
Net income, per share | ||||||||
- | - | - | 5.82 | 2.78 | -4.92 | 1.02 | 2.33 | 2.61 |
Basic weighted-averaged shares outstanding (in shares) | ||||||||
83 | 84 | 97 | 110 | 115 | 64 | 57 | 57 | 57 |
Diluted (loss) earnings per share (Note 5): | ||||||||
Income (loss) from continuing operations, per share | ||||||||
-12.00 | -43.12 | 18.09 | 4.39 | 2.00 | -0.34 | 0.14 | 2.45 | 2.72 |
Income from discontinued operations, per share | ||||||||
0.13 | 0.18 | 3.71 | 1.39 | 0.75 | -4.58 | 0.88 | -0.12 | -0.11 |
Net income, per share | ||||||||
-11.88 | -42.94 | 21.80 | 5.77 | 2.75 | -4.92 | 1.02 | 2.33 | 2.61 |
Diluted weighted-average shares outstanding (in shares) | ||||||||
83 | 84 | 97 | 111 | 117 | 64 | 57 | 57 | 57 |